Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $40.05 Average Target Price from Brokerages
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong […]
